CXCL8 and rheumatoid arthritis: This was further confirmed by the ability of pre-treating RA-FLS with a NF-κB inhibitor, PDTC (100 μmol/L) to inhibit CRP-induced proliferation (Figure 6A) and upregulation of CXCL8, CCL2.